Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

Britannia Pharmaceuticals

Status and phase: Completed; Phase 3; Phase 2

Conditions: Parkinson's Disease

Treatments: Drug: Apomorphine Nasal Powder

Study type: Interventional

Funder types: Industry

Identifiers

NCT00346827

20102D05

Details and patient eligibility

About

To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

Enrollment: 36 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day

Exclusion criteria

• hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females